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Background: Nanomaterials with particle sizes <100 nm have been already applied in various applications such as
cosmetics, medicines, and foods. Therefore, ensuring the safety of nanomaterials is becoming increasingly
important. Here we examined the localization and biological responses of intranasally administered amorphous
nanosilica particles in mice, focusing on the coagulation system.
Methods: We used nanosilica particles with diameters of 30, 70, or 100 nm (nSP30, nSP70, or nSP100 respectively), and
conventional microscale silica particles with diameters of 300 or 1000 nm (mSP300 or mSP1000, respectively). BALB/c
mice were intranasally exposed to nSP30, nSP70, nSP100, mSP300, or mSP1000 at concentrations of 500 μg/mouse for
7 days. After 24 hours of last administration, we performed the in vivo transmission electron microscopy analysis,
hematological examination and coagulation tests.
Results: In vivo transmission electron microscopy analysis showed that nanosilica particles with a diameter <100 nm
were absorbed through the nasal cavity and were distributed into liver and brain. Hematological examination and
coagulation tests showed that platelet counts decreased and that the activated partial thromboplastin time was
prolonged in nSP30 or nSP70-treated groups of mice, indicating that nanosilica particles might have activated a
coagulation cascade. In addition, in in vitro activation tests of human plasma, nanosilica particles had greater potential
than did conventional microscale silica particles to activate coagulation factor XII. In nanosilica-particle-treated groups,
the levels of soluble CD40 ligand, and von Willebrand factor which are involved in stimulating platelets tended to
slightly increase with decreasing particle size.
Conclusions: These results suggest that intranasally administered nanosilica particles with diameters of 30 and 70 nm
could induce abnormal activation of the coagulation system through the activation of an intrinsic coagulation cascade.
This study provides information to advance the development of safe and effective nanosilica particles.
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Over the past decade, the field of nanotechnology has
developed remarkably, and nanomaterials (NMs), which
are defined as objects with a diameter less than 100 nm,
have been created for various applications. For example,
NMs have already been included in many consumer prod-
ucts, such as cosmetics, food, and medicine, to improve
their stability and efficacy [1-3]. In particular, amorphous
nanosilica particles are one of the most widely applied
NMs and are used in cosmetics such as foundation and
sunblock, in food additives, and as diluents for medicine
[2,4]. As the number of commercial NMs increases, so do
opportunities for human exposure to NMs, leading to in-
creasing concern about the safety of NMs [5].
Concerns about the potential health risks of NMs have
caused international organizations, such as the World
Health Organization and the Organization for Economic
Co-operation and Development, to call for an urgent
and detailed evaluation of NMs’ safety. To create effect-
ive and safer NMs, information about the biodistribution
and biological effects of NMs must be acquired. Recent
studies have reported that NMs may have unpredicted
biological effects that conventional-sized materials do
not possess [6,7]. For example, like crocidolite asbestos,
carbon nanotubes induce mesothelioma-like lesions in
mice [8]. Other reports have shown that exposure to
titanium dioxide particles induces inflammatory re-
sponses and lung injury in mice [9,10]. In our previous
study, we revealed that nanosilica particles could penetrate
the skin and enter various tissues [11] and that nanosilica
particles can cause pregnancy complications [12], immune-
modulating effects [13,14], and consumptive coagulopathy
after being absorbed into the whole body of mice [15].
In addition, we showed that nanosilica particles-mediated
pregnancy complications and inflammation could be
avoided by surface modification of the nanosilica particles
with amino or carboxyl groups [12,16], suggesting that
modification of the surface of nanosilica particles with
amino or carboxyl groups may be effective for the creation
of safer nanosilica particles. However, only a few studies
have assessed the effects of nanosilica particles by realistic
exposure pathways, such as oral or intranasal pathways. In
particular, because nanosilica particles are used in the
spray products, and inhalation opportunities of nanosilica
particles in our life are increasing, such examination of
biodistribution and biological responses following nasal
exposure routes is urgently needed to advance the use of
nanosilica particles in various applications.
Here, we have investigated the in vivo localization and
biological effects of various sizes of nanosilica particles
following intranasal administration in mice. In addition,
we examined whether nanosilica particles could influ-
ence the coagulation system of mice. We expect that our
results will contribute to the creation of safer NMs.Results
Physicochemical examinations of silica particles
In this study, to assess the influence of the size of silica
particles on in vivo localization or biological effects, we
used nanosilica particles with diameters of 30, 70, or 100
nm (nSP30, nSP70, or nSP100, respectively), and con-
ventional microscale silica particles with diameters of
300 or 1000 nm (mSP300 or mSP1000, respectively). In
a previous study, we confirmed that the mean secondary
particle diameters of each of these types of silica parti-
cles are 39, 76, 106, 264, and 1136 nm (for nSP30,
nSP70, nSP100, mSP300, and mSP1000, respectively) by
dynamic laser scattering analysis [11,12,14], and all the
particles were confirmed to be well-dispersed smooth-
surfaced spheres by transmission electron microscopy.
These results indicate that the silica particles used in this
study would remain stable and well-dispersed in solu-
tion, without aggregating.
In vivo localization of silica particles
First, we qualitatively examined the in vivo localization of
silica particles after intranasal administration (Figure 1).
BALB/c mice were intranasally exposed to nSP30, nSP70,
nSP100, mSP300, or mSP1000 at concentrations of 500
μg/mouse for 7 days. Transmission electron microscopy
analysis revealed that mSP1000 were located in mucosal
epithelial cells of the nasal cavity (Figure 1a), and mSP300
and mSP1000 were located in type II alveolar epithelial
cells of the lung (Figure 1b,e), although they were not
detected in the liver (Figure 1c,f ). On the other hand,
nSP30, nSP70, and nSP100 were located not only in the
nasal cavity (Figure 1g,j,m,p,s,v) and lung (Figure 1h,k,n,q,
t,w) but also in hepatocytes in the liver (Figure 1i,l,o,r,u,x).
These results suggested that nanosilica particles were
absorbed through the nasal cavity and distributed into
some tissues in the body. Therefore, to thoroughly evalu-
ate the safety of these NMs, the biological effects of the
intranasally administered silica particles might need to be
evaluated for all tissues in the mouse body.
Biological effects induced by silica particles in tissue
To evaluate the effects of silica particles on the tissue in
which they were present after intranasal administration,
we observed the nasal cavity, brain, and liver of each
mouse by hematoxylin–eosin staining (Figure 2). For all
the groups of mice, although very slight inflammatory
cell aggregation was observed in the nasal cavity, brain,
and liver, these pathological findings were within normal
ranges (Figure 2 and Table 1). Next, we measured the liver
damage markers alanine aminotransferase (ALT) and al-
bumin (ALB), as well as kidney damage marker blood urea
nitrogen (BUN), in the tissues (Figure 3). Although the
level of ALT in plasma increased slightly in nanosilica-
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Figure 1 Biodistribution of silica particles. BALB/c mice were intranasally exposed to nSP30, nSP70, mSP300, nSP100, or mSP1000 at a
concentration of 500 μg/mouse for 7 days. Twenty-four hours after the final administration, the nasal cavity (a,d,g,j,m,p,s,v), lung
(b,e,h,k,n,q,t,w), and liver (c,f,i,l,o,r,u,x) were evaluated by transmission electron microscopy. Arrows point to silica particles. N.D.: not detected.
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range (<43 U/L) among all the groups (Figure 3a). BUN
and ALB levels did not change significantly for any of the
groups (Figure 3b,c). These results suggest that the intra-
nasally administered nanosilica particles did not induce
abnormal changes in some tissues.
Next, we performed hematological examination. As
the size of the nanosilica particles decreased, so did the
platelet counts in the silica-particle-treated groups, al-
though the counts of other blood components (white
blood cells, lymphocytes, and monocytes) remained un-
changed in all groups (Figure 4a–d). The decrease in plate-
lets was confirmed to occur in a dose-dependent manner
in the nSP70- and nSP30-treated groups (Figure 4e,f ).The platelet counts for nSP70 at concentrations below
250 μg/mouse and for nSP30 at concentrations below
62.5 μg/mouse were equal to those of the control group
(Figure 4e,f). Thus, these findings suggest that intranasally
administered nanosilica particles may decrease platelet
counts.
Activation of coagulation system induced by silica
particles
Previously, we revealed that a drastic decrease in plate-
lets after systemic exposure to nSP70 could result from
consumptive coagulopathy [15]. Therefore, we specu-
lated that intranasally administered nanosilica particles































Figure 2 Histopathological analysis. BALB/c mice were intranasally exposed to nSP30, nSP70, mSP300, nSP100, or mSP1000 at a concentration
of 500 μg/mouse for 7 days. Twenty-four hours after the final administration, nasal cavity (a,d,g,j,m,p), liver (b,e,h,k,n,q) and brain (c,f,i,l,o,r) tissue
samples were stained with hematoxylin–eosin. In images, solid line delineates cell aggregation. The histopathological grades of these samples are
summarized in Table 1.
Table 1 Histopathological grades of nasal cavity, brain,
and liver tissue samples collected from three different
BALB/c mice exposed to nSP30, nSP70, mSP300, nSP100,
or mSP1000 via intranasal administration












1 2 0 1 2 1 1 1 0 1 1 1 0 0 0 0 1 1
Rarefaction 3 3 2 3 3 2 3 3 3 3 3 3 3 2 2 3 3 2
Grade; 0: none, 1: very slight, 2: mild, 3: moderate, 4: advanced.
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we measured the bleeding time of whole blood from each
silica-particle-treated mouse by Duke’s method (Figure 5a).
Bleeding time was prolonged in the nSP30- and
nSP70-treated groups compared to the control group,
although the bleeding times of the nSP100-, mSP300-, and
mSP1000-treated groups did not change (Figure 5a). These
results suggest that intranasal exposure to nanosilica parti-
cles could induce abnormal activation of the coagulation
system and thus leads to the consumptive coagulopathy.
Next, we examined the mechanism of abnormal acti-
vation of the coagulation system induced by nanosilica
particles after intranasal administration. The blood co-
agulation system can be initiated by two pathways: an
extrinsic cascade pathway, which is triggered by the re-












































Figure 3 Biochemical analysis. BALB/c mice were intranasally exposed to nSP30, nSP70, mSP300, nSP100, or mSP1000 at a concentration of
500 μg/mouse for 7 days. Twenty-four hours after the final administration, plasma was collected. (a) alanine aminotransferase (ALT), (b) blood
urea nitrogen (BUN), and (c) albumin (ALB) were analyzed. Results are expressed as mean ± S.E. (n = 4–5). *Represents significant difference from
the control (p < 0.05).
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tion of coagulant factor contacted with a negatively
charged substance or accumulation of activated platelets
to the collagen layer under the vascular endothelium
[17]. We examined which cascade pathway was involved
in the abnormal activation of the coagulation cascade
by nanosilica particles after intranasal administration.
The levels of prothrombin time (PT) (Figure 5b) and TF
(Figure 5c), parameters for the activation of an extrinsic
coagulation pathway, and activated partial thromboplastin
time (APTT) (Figure 5d), a parameter for the activation
of an intrinsic coagulation pathway, were measured in
the plasma of each silica-particle-treated mouse. The
levels of PT and TF did not vary compared to those ob-
served for the control group (Figure 5b,c). In contrast,
APTT in plasma from the nSP30- or nSP70-treated group
was remarkably prolonged compared to that of the control
group, although no change in APTT was observed for
the nSP100-, mSP300-, or mSP1000-treated group
(Figure 5d). These results suggest that the activation
of an intrinsic cascade pathway induced by nanosilica
particles could result in abnormal activation of the
coagulation system.Generally, the activation of an intrinsic cascade path-
way is initiated by coagulation factor XII when it comes
into contact with hydrophilic activating particles (such
as fully water-wettable glass) [18]. Platelet activation is
also involved in the activation of intrinsic cascade path-
ways [19]. We thus performed in vitro activation tests of
coagulation factor XII using human plasma to confirm
the presence of an intrinsic cascade pathway. One of our
overall research goals is to contribute to the develop-
ment of NMs that will be effective as well as safe for
human exposure. To conduct a preliminary evaluation
of the effects of nanosilica particles on humans, we used
human plasma in the experiment, rather than mouse
plasma. The in vitro activation tests showed that all sizes
of the silica particles had the potential to activate coagu-
lation factor XII, with activation apparently increasing
as the size of the particles decreased (Figure 6a). In
addition, to evaluate the activation of platelets, we
measured the level of soluble CD40 ligand (sCD40L)
and von Willebrand factor (vWF), which are involved in
stimulating platelets [20,21], in the plasma of each silica-
particle-treated mouse. In nanosilica-particle-treated



















































































































Figure 4 Hematological analysis. BALB/c mice were intranasally exposed to nSP30, nSP70, mSP300, nSP100, or mSP1000 at a concentration of
500 μg/mouse in (a-d), and 31.3-500 μg/mouse in (e,f) for 7 days. Twenty-four hours after the final administration, (a,e,f) platelets, (b) white
blood cells, (c) lymphocytes, and (d) monocytes were analyzed. Results are expressed as mean ± S.E. (n = 5). *Represents significant difference
from the control (p < 0.05).
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results suggest that the activation of an intrinsic coagula-
tion pathway by nanosilica particles after intranasal admin-
istration was promoted by the activation of coagulation
factor XII and platelets.
Discussion
Merget et al. suggested that the inhalation of amorphous
silica particles in the workplace could induce silicosis
[22]. In addition, nanosilica particles have been exploredfor medical applications, such as cancer therapeutics or
drug-delivery agents via intranasal administration [23,24].
However, there is not enough information about the bio-
logical effects of nanosilica particles after intranasal expos-
ure for them to be used safely. In this study, we focused
on intranasal exposure of nanosilica particles and deter-
mined the localization and biological effects of nanosilica
particles after intranasal administration.
Warheit et al. and Lee et al. reported that the no-































































Figure 5 Examination of coagulation cascade. BALB/c mice were intranasally exposed to nSP30, nSP70, mSP300, nSP100, or mSP1000 at a
concentration of 500 μg/mouse for 7 days. Twenty-four hours after the final administration, (a) bleeding time (evaluated by Duke’s method),
(b) prothrombin time (PT) and (d) activated partial thromboplastin time (APTT) were evaluated. (c) The level of tissue factor (TF) in plasma was
determined using ELISA. PT and APTT in collected plasma were determined at 37°C in the Clotek dry-block heating system with PT and APTT
reagents. Results are expressed as mean ± S.E. (n = 4–5). *Represents significant difference from the control (p < 0.01).
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of 10 mg/m3) [25,26]. Accordingly, we designed our
experiments such that mice were intranasally exposed
to various sizes of silica particles at 500 μg/mouse for
7 days, a level close to the NOEL for inhalation ex-
posure. The dose in our study is important from the
viewpoint of establishing an upper threshold for the
amount of NMs that can safely be administered intrana-
sally. Although we still need to accumulate much more
information about the biological effects of nanosilica parti-
cles using intranasal administration, at realistic exposure
levels, we expect that our present study will contribute to
the safety assessment of NMs.
We found that nSP30, nSP70, and nSP100 were located
not only in the nasal cavity and lung but also in the liver
(Figure 1). In our previous study, we showed that nSP70,
mSP300, and mSP1000 localized in the liver after enteringthe bloodstream [11]. When we hypothesize how the
nanosilica particles (smaller than 100 nm) enter the liver
after intranasal administration, it is important to discuss
how nanosilica particles enter the bloodstream through
the nasal cavity or lung. We hypothesized that the
nanosilica particles were absorbed through transcytosis, or
uptake by microfold cells (M cells) in bronchus-associated
lymphoid tissues and nasal-associated lymphoid tissues.
Other reports have suggested that NMs open the tight
junction, which plays an important role in maintaining the
epithelial barrier [27,28]. Thus, to investigate the pathway
by which nanosilica particles enter the body, we need to
evaluate the effects of nanosilica particles on M cells or
epithelial cell barriers in vitro. In this study, we examined
only the nasal cavity, lung, and liver, so we cannot com-
ment as to whether nanosilica particles are localized in






































































Figure 6 Examination of intrinsic cascade pathways. (a) In vitro changes in blood coagulation factor XII activity in human plasma by silica
particles of various sizes. The initial rate of reaction of coagulation factor XII was obtained from human plasma, which was obtained from a
control sample of human plasma, which did not contain any silica particles, and was measured by fluorescence intensity. Results are expressed as
mean ± S.D. (n = 5). ** and * represent significant differences from the control (**p < 0.01, *p < 0.05). RFU: relative fluorescent unit. (b) The level
of soluble CD40 ligand (sCD40L) and (c) the level of von Willebrand factor (vWF) in mouse plasma. BALB/c mice were intranasally exposed to
nSP30, nSP70, mSP300, nSP100 or mSP1000 at a concentration of 500 μg/mouse for 7 days. Twenty-four hours after the final administration, the
levels of sCD40L and vWF in the mouse plasma were determined using ELISA. Results are expressed as mean ± S.E. (n = 4–5). ** and * represent
significant differences from the control (**p < 0.01, *p < 0.05).
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were localized in the brain after intranasal administration
[29,30]. Furthermore, Liu et al. showed that copper
nanoparticles with a diameter of 23.5 nm enter the olfac-
tory bulb in the brain [31]. Therefore, in our study, it is
possible that nanosilica particles with diameters of 30 or
70 nm may have been localized in the brain. In this ana-
lysis, the particles detected in tissues after intranasal ad-
ministration of mSP300 and mSP1000 were smaller than
the average diameter of the respective administered parti-
cles (Figure 1a,b,e). We consider the possibility of degrad-
ation of mSP300 and mSP1000 in the body, because some
previous in vitro studies have suggested that silica particles
could be degraded in humans and animals after absorp-
tion [32-34]. For example, Kim et al. showed that approxi-
mately 50% to 80% of a sample of microsilica particles was
dissolved within 36 h in a solution of phosphate-buffered
saline with 10% bovine serum, which is a simulated body
fluid [32]. In addition, a recent study suggested thepossibility of silica particle degradation at a cellular level.
Zhai et al. showed that hollow mesoporous nanosilica par-
ticles degraded when injected into human umbilical vein
endothelial cells [33]. On the basis of these reports’ find-
ings, silica particles localized in biological bodies might be
degraded within 7 days by means of interaction with bio-
logical fluid or by uptake into epithelial cells in the nasal
cavity or lungs. On the other hand, because transmission
electron microscopy analysis is only a qualitative method,
we need to quantitatively analyze the silica particles after
intranasal exposure to obtain more detailed information
about their biodistribution. Inductively coupled plasma–
optical emission spectrometry (ICP-OES) is reported to be
a suitable means for quantitatively measuring silica. Using
ICP-OES, we initially attempted to quantify the absorption
of nSP30 and nSP70 in the liver after intranasal exposure
for 7 days. However, we did not detect the particles in bio-
logical tissue using ICP-OES (data not shown; the detec-
tion limit of our protocol was 50 μg/g). In our study,
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sufficient for measurement by ICP-OES. To quantitatively
analyze the nanosilica particles and clarify their absorp-
tion, distribution, metabolism, and excretion mechanisms,
a method with greater sensitivity must be developed.
Previously, we found that nanosilica particles could ac-
cumulate in the liver and induce severe liver damage
after intravenous administration [11,15]. The level of
nanosilica particles accumulated in the liver after intra-
nasal administration would be lower than that observed
after intravenous administration, and thus a nanosilica-
particle-mediated increase of ALT levels or abnormal find-
ings in pathological examination would have been reduced
in the present study. We must measure the level of
nanosilica particles in the liver quantitatively to confirm
this speculation; overall, our present findings suggest that
we need to more precisely evaluate the biological effects
of intranasally administered NMs on all tissues in the
body, including the liver and brain.
Intranasally administered nanosilica particles might
have induced abnormal activation of the intrinsic coagu-
lation cascade (Figures 4 and 5). To explain the decrease
of platelets observed in the nanosilica-particle-treated
groups, the nanosilica particles might directly activate
the platelets and promote the coagulation cascade,
resulting in consumption of platelets and consequently
prolonged bleeding times. Other groups have shown that
some NMs, such as single-walled carbon nanotubes and
rutile titanium dioxide nanorods, could activate platelets
and induce abnormal activation of the coagulation sys-
tem [35-38]. Therefore, in our study the platelets might
have been activated by the nanosilica particles and then
subsequently consumed as they formed blood clots, thus
decreasing the number of platelets and consequently
prolonging bleeding time. Furthermore, the platelet counts
in the nSP70-treated group at concentrations <250 μg/
mouse and in the nSP30-treated group at concentra-
tions <62.5 μg/mouse were equal to the count of the con-
trol group. Thus, this finding could provide useful
information for setting the no-observable-adverse-effect
level for intranasally administered nanosilica particles. Our
present results indicate that the abnormal activation of a
coagulation cascade by nanosilica particles after intranasal
administration was promoted by activation of an intrinsic
cascade pathway (Figure 5). However, our previous study
showed that intravenously administered nSP70 could in-
duce the release of TF, which is a known marker of activa-
tion of an extrinsic cascade pathway [15]. We speculate
that the level of intranasally administered nanosilica parti-
cles in the bloodstream was lower than that of intraven-
ously administered nanosilica particles, and thus a drastic
release of TF was not detected in this study.
Contact activation of coagulation factor XII is one of
the major factors of blood coagulation [39,40], and, asmentioned earlier, coagulation factor XII is activated
when it comes into contact with hydrophilic activating
particles (such as fully water-wettable glass) [18]. Since
the number of silica particles per unit weight increases
as the particle size decreases (the particle numbers of
the silica particles were 3.5 × 1013, 2.8 × 1012, 9.5 × 1011,
3.5 × 1010, and 9.5 × 108 particles/mg for nSP30, nSP70,
nSP100, mSP300, and mSP1000, respectively), the num-
ber of opportunities for contact between the nanosilica
particles and coagulation factor XII would have in-
creased with decreasing particle size, thus ultimately
leading to the activation of coagulation factor XII. In
addition, we need to take into account not only the
number of silica particles but also the surface area. The
intrinsic cascade pathway involves various factors, such
as factor XI and prekallikrein. Therefore, to reveal the
mechanism of abnormal activation of the coagulation
cascade by nanosilica particles, we need to examine the
effects of nanosilica particles on other factors in intrinsic
cascade pathways. Increases in the levels of sCD40L and
vWF were observed in plasma from the nSP30- and
nSP70-treated groups (Figure 6), meaning that nanosilica
particles absorbed into the bloodstream induced activa-
tion of platelets, which are involved in the activation of
coagulation pathways. Although we need to evaluate in
greater detail the effects of nanosilica particles on activa-
tion or aggregation of platelets, our results and these previ-
ous reports suggest that nanosilica particles would induce
platelet activation, resulting in activation of an intrinsic
cascade pathway. Tavano et al. suggested that synthetic
amorphous silica (SAS), which is similar to our silica
nanoparticles, and organically modified silica (ORMOSIL)
nanoparticles induce significant abnormal activation of the
coagulation system via a different mechanism in in vitro
studies [41]. More specifically, SAS nanoparticles acti-
vate contact coagulation (factor XII dependent) but not
TF transcription in monocytes. In contrast, ORMOSIL
nanoparticles induce TF-dependent coagulation more effi-
ciently than SAS nanoparticles. The group’s report indi-
cated that the activation of an intrinsic cascade pathway is
the main mechanism of amorphous silica nanoparticle–
mediated procoagulant activity, thus supporting our
study’s conclusions and reiterating the importance of
examining the effects of silica nanoparticles on intrinsic
coagulation.
In summary, we revealed that intranasally adminis-
tered nanosilica particles have the potential to induce
abnormal activation of a coagulation cascade in mice.
Recently, nanosilica particles have been used in food ad-
ditives and cosmetics, and thus opportunities for such
particles to be inhaled by workers during manufacturing
are increasing [4,42]. Furthermore, nanosilica particles
are being explored as cancer therapy and drug-delivery
agents, and might be administered intranasally in such
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biological effects of intranasally administered nanosilica
particles must be elucidated. We expect that further stud-
ies of the relationship between localization and biological
effects will provide useful information for the development
of safer, effective NMs.
Conclusions
We have shown that nanosilica particles with diameters
of 30, 70, and 100 nm intranasally administered to mice
were absorbed into the bloodstream and distributed into
certain organs, such as the liver. The obtained results
suggest that the activation of an intrinsic cascade path-
way induced by nanosilica particles with diameters of
30 and 70 nm, both of which activated coagulation factor
XII and platelets, could result in abnormal activation of
the coagulation system. We expect that the findings of this
study will contribute to the ongoing development of NMs
that are safe for use in humans and animals.
Methods
Silica particles
Amorphous nanosilica particles with diameters of 30,
70, and 100 nm, as well as microscale silica particles
with diameters of 300 and 1000 nm (Micromod
Partikeltechnologie, Rostock/Warnemünde, Germany,
designated nSP30, nSP70, nSP100, mSP300, and
mSP1000, respectively) were used in this study. The
particle numbers of the silica particles were 3.5 ×
1013, 2.8 × 1012, 9.5 × 1011, 3.5 × 1010, and 9.5 × 108
particles/mg for nSP30, nSP70, nSP100, mSP300, and
mSP1000, respectively. Each type of silica particles
was sonicated for 5 min and vortexed for 1 min be-
fore use.
Animals
BALB/c mice (female, 6–8 weeks) were purchased from
Japan SLC, Inc. (Shizuoka, Japan). Mice were housed in
a ventilated animal room maintained at 20 ± 2°C with a
12-h light/12-h dark cycle. Mice had free access to water
and alfalfa-free forage (FR-2, Funabashi Farm, Funabashi,
Japan). All of the animal experimental procedures in this
study were performed in accordance with the National
Institute of Biomedical Innovation and Osaka University
Guidelines for the Welfare of Animals.
Transmission electron microscopy analysis
Five BALB/c mice were intranasally exposed to a 20 μL
aliquot (10 μL per nostril) of nSP30, nSP70, nSP100,
mSP300, or mSP1000 at a concentration of 500 μg/mouse
for 7 days. Twenty-four hours after the final intranasal
administration, the nasal cavity, lung, and liver from two
mice were excised and fixed in 2.5% glutaraldehyde for
2 h. Then, small pieces of tissue sample were washedwith phosphate buffer 3 times and postfixed in sodium
cacodylate-buffered 1.5% osmium tetroxide for 60 min at
4°C, block-stained in 0.5% uranyl acetate, dehydrated by
dipping each sample through a series of ethanol solutions
containing increasing concentration of ethanol, and em-
bedded in Epon resin (TAAB). Ultrathin sections were
stained with uranyl acetate and lead citrate. The stained
samples were subsequently observed under an electron
microscope (H-7650, Hitachi, Tokyo, Japan).
Histopathological examination
Twenty-four hours after the final intranasal administra-
tion of each type of silica particles, the nasal cavity, lung,
and liver from three mice were excised and fixed imme-
diately in 4% paraformaldehyde. These tissues were
embedded in paraffin blocks and then sliced, and the
slices were placed on glass slides. After hematoxylin–
eosin staining, the slides were observed, and cell aggre-
gation in the nasal cavity, microglial aggregation in the
brain, and cell aggregation and rarefaction in the liver
were classified into one of five grades (0: none, 1: very
slight, 2: mild, 3: moderate, 4: advanced).
Blood biomarker assay
Twenty-four hours after the final intranasal administration
of each type of silica particles, blood samples were col-
lected from the heart using plastic syringes (Terumo,
Tokyo, Japan) containing 5 IU/mL heparin sodium. Plasma
was harvested by centrifuging the blood at 1750 × g
for 15 min. The levels of ALT, ALB and BUN were
determined in the plasma using a biochemical auto-
analyzer (Fuji dri-Chem 7000, Fujifilm, Tokyo, Japan).
Hematology analysis
Twenty-four hours after the final intranasal administration
of each type of amorphous silica particles, blood samples
were collected from the heart using plastic syringes
(Terumo) containing 0.1 mM EDTA. Whole blood samples
were analyzed with a VetScan HMII Hematology System
(Abaxis, Sunnyvale, CA, USA) to determine the number of
white blood cells, lymphocytes, monocytes, and platelets.
Measurement of bleeding time and coagulation tests
Twenty-four hours after the final intranasal adminis-
tration of each type of silica particles, the bleeding
time for each mouse was measured by Duke’s method
[43]. Briefly, an ear of each mouse was cut with a
knife, and the blood generated at the site of the cut
was absorbed with filter paper every 30 seconds until
bleeding ceased. To examine the coagulation tests in
each mouse, a blood sample was collected from the
heart of each mouse subjected to bleeding-time tests
using plastic syringes (Terumo) containing 1:9 (v/v)
of 3.8% sodium citrate. Plasma was harvested by
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PT levels were determined at 37°C in a Clotek dry-block
bath system (Hyland Division, Travenol Laboratories, Inc.
Costa Mesa, CA, USA) with APTT and PT reagents
(Sysmex, Kobe, Japan), respectively.
In vitro activation tests of coagulation factor XII
One hundred microliters of human health plasma (Scipac,
Kent, UK) and 100 μL of various sized silica particles (3.13
mg/mL) were mixed for 1 min at room temperature with
an enzyme reaction solution (50 mM Tris–HCl, 0.15 M
NaCl, 1 mM CaCl2 and 0.1 mg/mL bovine serum albumin,
pH 8.0) containing 2 mM t-butyloxycarbonyl-L-glutaminyl-
glycyl-L-arginine-4-methyl-courmaryl-7-amide (Peptide
Institute, Inc. Ibaraki, Japan) in dimethyl sulfoxide. The
initial rate of reaction was calculated by measuring
the fluorescence intensity (380 nm excitation, 440 nm
emission) every 5 min. The initial rate is given by Initial
rate = (relative fluorescent unit of each measurement
time – blank) / measurement time.
Detection of TF, sCD40L, and vWF levels in plasma
TF, sCD40L, and vWF levels in plasma were determined
using enzyme-linked immunosorbent assay (ELISA) kits
(TF: Mouse Tissue Factor ELISA kit (Cusabio, Newark,
DE, USA); sCD40L: Mouse sCD40L ELISA (eBioscience,
San Diego, CA, USA); vWF: Mouse von Willebrand
Factor ELISA kit (Cusabio, Newark, DE, USA)).
Statistical analysis
Differences among each group were compared by using
Williams’s or Dunnett’s method after analysis of variance
(ANOVA).
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